Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels

Ormeci, Aslı; Aydın, Yücel; Sumnu, Abdullah; Baran, Bülent; Soyer, Ozlem; Pinarbasi, Binnur; Gokturk, Suut; Gulluoglu, Mine; Onel, Derya; Badur, Osman; Akyuz, Filiz; Karaca, Cetin; Demir, Kadir; Besisik, Selman; Kaymakoglu, Sabahattin

doi:10.1016/j.ijid.2016.09.007

Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels

Atıf İçin Kopyala

Ormeci A., Aydın Y., Sumnu A., Baran B., Soyer O. M., Pinarbasi B., ...Daha Fazla

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, cilt.52, ss.68-73, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 52
Basım Tarihi: 2016
Doi Numarası: 10.1016/j.ijid.2016.09.007
Dergi Adı: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.68-73
Anahtar Kelimeler: Chronic hepatitis B, HBeAg-negative, Persistently normal ALT, NORMAL ALT, NATURAL-HISTORY, VIRUS INFECTION, GUIDELINES, MANAGEMENT, SEROCONVERSION, RISK
İstanbul Üniversitesi Adresli: Evet

Özet

Objectives: Serum alanine aminotransferase (ALT) is a controversial marker for disease monitoring in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. The aim of this study was to determine the fibrosis stage and histological activity index (HAI) in HBeAg-negative CHB patients with persistently normal ALT (PNALT) and high serum HBV DNA (>= 2000 IU/ml) and to investigate clinical risk factors for the requirement of treatment through the examination of liver biopsy specimens.